Product Name :
ENMD-1198
Description:
ENMD-1198 (IRC-110160), an orally active microtubule destabilizing agent, is a 2-methoxyestradiol analogue with antiproliferative and antiangiogenic activity. ENMD-1198 is suitable for inhibiting HIF-1alpha and STAT3 in human HCC cells and leads to reduced tumor growth and vascularization.
CAS:
864668-87-1
Molecular Weight:
311.42
Formula:
C20H25NO2
Chemical Name:
(3aS, 3bS, 9bS, 11aR)-8-methoxy-11a-methyl-3H, 3aH, 3bH, 4H, 5H, 9bH, 10H, 11H, 11aH-cyclopenta[a]phenanthrene-7-carboxamide
Smiles :
COC1=CC2[C@H]3CC[C@]4(C)C=CC[C@H]4[C@@H]3CCC=2C=C1C(N)=O
InChiKey:
YQJWOUQGXATDAE-ACNBBOPNSA-N
InChi :
InChI=1S/C20H25NO2/c1-20-8-3-4-17(20)14-6-5-12-10-16(19(21)22)18(23-2)11-15(12)13(14)7-9-20/h3,8,10-11,13-14,17H,4-7,9H2,1-2H3,(H2,21,22)/t13-,14+,17-,20-/m0/s1
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.{{Spermine} site|{Spermine} Metabolic Enzyme/Protease|{Spermine} Protocol|{Spermine} In stock|{Spermine} supplier|{Spermine} Cancer}
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
ENMD-1198 (IRC-110160), an orally active microtubule destabilizing agent, is a 2-methoxyestradiol analogue with antiproliferative and antiangiogenic activity. ENMD-1198 is suitable for inhibiting HIF-1alpha and STAT3 in human HCC cells and leads to reduced tumor growth and vascularization.|Product information|CAS Number: 864668-87-1|Molecular Weight: 311.42|Formula: C20H25NO2|Synonym:|IRC-110160|Chemical Name: (3aS, 3bS, 9bS, 11aR)-8-methoxy-11a-methyl-3H, 3aH, 3bH, 4H, 5H, 9bH, 10H, 11H, 11aH-cyclopenta[a]phenanthrene-7-carboxamide|Smiles: COC1=CC2[C@H]3CC[C@]4(C)C=CC[C@H]4[C@@H]3CCC=2C=C1C(N)=O|InChiKey: YQJWOUQGXATDAE-ACNBBOPNSA-N|InChi: InChI=1S/C20H25NO2/c1-20-8-3-4-17(20)14-6-5-12-10-16(19(21)22)18(23-2)11-15(12)13(14)7-9-20/h3,8,10-11,13-14,17H,4-7,9H2,1-2H3,(H2,21,22)/t13-,14+,17-,20-/m0/s1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: Soluble in DMSO.|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{Tafamidis} web|{Tafamidis} Transthyretin (TTR)|{Tafamidis} Biological Activity|{Tafamidis} In Vivo|{Tafamidis} custom synthesis|{Tafamidis} Autophagy} |Shelf Life: ≥12 months if stored properly.PMID:32310568 |Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|ENMD-1198 (0-5 μM; 24 hours) leads to a significant dose-dependent inhibition of HCC cell growth with IC50s of 2.5 μM for HUH-7 and HepG2 cells, respectively. ENMD-1198 (2.5 μM; 16 hours) abrogates EGF-induced phosphorylation of Akt (HUH-7), FAK (HUH-7), p44/42 MAPK (HepG2), and STAT3 (HUH-7, HepG2).|In Vivo:|ENMD-1198 (200 mg/kg; p.o.; daily from day 7 to day 19) effectively inhibits growth of hepatocellular carcinoma through direct effects on the tumor cells, and also through inhibition of angiogenesis.|References:|Pasquier E, et al. ENMD-1198, a new analogue of 2-methoxyestradiol, displays both antiangiogenic and vascular-disrupting properties. Mol Cancer Ther. 2010 May;9(5):1408-18.Snoeks TJ, et al. 2-methoxyestradiol analogue ENMD-1198 reduces breast cancer-induced osteolysis and tumor burden both in vitro and in vivo. Mol Cancer Ther. 2011 May;10(5):874-82.Products are for research use only. Not for human use.|